Merck & Company News - October 2026

🟢 Merck is trading 3.01% up today after Phase 3 melanoma vaccine trial success

Merck is trading 3.01% up at $146.25 after Merck and Moderna’s personalized cancer vaccine, used with Keytruda, succeeded in a Phase 3 melanoma trial. - Merck...

Halozyme Wins Order Blocking Merck's Injectable Keytruda in Eight European Markets

A Dutch patent court ruled in favor of Halozyme Therapeutics, finding that Merck's subcutaneous (under-the-skin) version of its cancer drug Keytruda infringes...